Dr. Reddy’s has entered into an exclusive partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across India. Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.
The partnership continues Dr. Reddy’s efforts to become the partner of choice in increasing access to novel, innovative as well as trusted drugs for patients in India. The partnership gives Dr. Reddy’s a strong portfolio and major presence in the vaccine segment taking it to second position among vaccine players in India.
These brands saw combined sales of Rs 426 crores (approx $51 million) as per IQVIA MAT February 2024. Sanofi will continue to own, manufacture and import these brands to the country.
Preeti Futnani, General Manager India for Vaccines, Sanofi, said, “Vaccine confidence has reached its highest in India in the last few years. To fulfil our long-term commitment to India and expand our geographic reach, we’re pleased to partner with Dr. Reddy’s for exclusive distribution and promotion.”
Dr. Reddy’s will leverage its strengths in promotion and distribution to considerably expand engagement with healthcare professionals and help widen access of Sanofi’s well-established and trusted vaccine brands in India.
MV Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “The portfolio now gives Dr. Reddy’s a strong presence in the vaccine segment, propelling us to the second position among vaccines players in India. Through each product and partnership, our aim is to serve over 1.5 billion patients by 2030.”
